***Background.*** Inactivated influenza vaccines are manufactured either as split-virion or subunit. Both vaccines are assumed to have similar clinical effectiveness due to similar hemagglutination inhibition assay results. However, split-virion vaccines contain more internal protein and stimulate a greater cellular immune response, but the clinical significance of this is unknown.

***Methods.*** Adults ≥ 50 years of age seeking medical care for acute respiratory illness November through April 2008-09, 2010-11 & 2011-12 were eligible. Influenza cases and controls were identified by positive and negative RT-PCR, respectively. We ascertained exposure to seasonal influenza split virion vaccine (Afluria, Fluarix, FluLaval, & Fluzone Standard Dose) or subunit vaccine (Agriflu & Fluvirin) ≥2 weeks prior to the visit. Fluzone High Dose recipients were excluded. Covariates included age, sex, race, smoking, oxygen use, insurance, medical conditions, immunosuppression, week of ARI visit, influenza season, & site of enrollment. Vaccine effectiveness (VE) for split vaccine versus no vaccine and subunit vaccine versus no vaccine were estimated as \[(1-adjusted odds ratio) x 100\] using logistic regression models with L1 penalty on all covariates except vaccine type (LASSO). The relative VE was calculated as the VE difference.

***Results.*** We enrolled 840 participants of whom 539 had a known immunization status and complete clinical data. Compared to influenza negative patients, the 68 (12.6%) influenza positive patients were younger (p \< 0.001), more likely to have been enrolled in the hospital than in either the emergency department or the acute care clinic (p = 0.001), and more likely to have received subunit than split-virion vaccine (\<0.001). Patients who received split-virion vaccines (n = 204) were similar to those (n = 150) who received subunit vaccines except for the proportion who were influenza positive (5.4% vs.12%, p = 0.02). VE for the split influenza vaccine was 77.8% (58.5%, 90.3%) while that of the subunit vaccine was 44.3% (-11.8%, 70.9%). Relative VE for split-viron compared to subunit vaccines was 33.5%, (95% CI: 6.9%, 86.7%).

***Conclusion.*** Split-virion influenza vaccines had greater ***clinical effectiveness***than subunit vaccines in adults ≥50 years of age.
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